GlassScriptPhysician profile
Taylor Moran Fahey
NPI 1477368629
$1,387.34
in general payments reported to CMS, 2019-2025
26 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $233.93 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $156.00 | 2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $142.78 | 2025 | |
| Abbvie INC. | $88.35 | 2025 | |
| Lilly USA, LLC | $81.60 | 2025 | Jardiance, Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $69.40 | 2025 | Rexulti |
| Madrigal Pharmaceuticals | $67.35 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $55.13 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $49.32 | 2025 | Korlym |
| Collegium Pharmaceutical, INC. | $48.69 | 2025 | Jornay Pm |
| Astellas Pharma US INC | $47.38 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.84 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $43.98 | 2025 | Lagevrio |
| Glaxosmithkline, LLC. | $38.55 | 2025 | Trelegy Ellipta |
| Corium, LLC | $29.61 | 2025 | Azstarys |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $21.19 | 2025 | Nuplazid |
| Axsome Therapeutics, INC. | $19.86 | 2025 | Auvelity |
| Lundbeck LLC | $18.98 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $18.88 | 2025 | Voquezna |
| Kyowa Kirin, INC. | $18.79 | 2025 | |
| Sumitomo Pharma America, INC. | $17.35 | 2025 | Gemtesa |
| Pfizer INC. | $16.04 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $14.85 | 2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.99 | 2025 | Jardiance |
| Amgen INC. | $13.62 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Fahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.